First Quadrant’s Acceleron Pharma XLRN Stock Holding History

First Quadrant’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-212	Closed	-$24K	–	699
2020 Q3	$24K	Buy	+212	New	+$21.1K	﹤0.01%	539

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Quadrant's XLRN Position: Q4 2020 in Review

First Quadrant sold out of Acceleron Pharma (XLRN) in Q4 2020, closing a stake of 212 shares — an estimated $24K sold.

First Quadrant first reported a position in XLRN in Q3 2020 and held it in 1 quarter. The position peaked at $24K in Q3 2020. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

First Quadrant reported no remaining Acceleron Pharma position as of Q4 2020 after selling out during the quarter.
First Quadrant sold 212 Acceleron Pharma shares in Q4 2020, an estimated $24K.
First Quadrant first reported a position in Acceleron Pharma in Q3 2020 and held it in 1 quarter.
First Quadrant's Acceleron Pharma position peaked at $24K in Q3 2020.
253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on First Quadrant's 13F filing for Q4 2020, filed 27 Jan 2021.